|Articles|July 1, 2001
- Applied Clinical Trials-07-01-2001
ACT 101 Human Safety in Clinical Research
Pharmaceutical companies must pay close attention to the safety of human subjects at every stage of drug development, as explained in this QA view of the policies and regulations that make the system work.
Advertisement
Articles in this issue
about 25 years ago
Letters to the Editorabout 25 years ago
Conference Reportsabout 25 years ago
Affairs of Stateabout 25 years ago
Pen-Based Computingabout 25 years ago
Some Do--Some Watch Over Those Who Doabout 25 years ago
Communication Skills for Monitors—A Vital Training OpportunityAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy
2
ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion
3
Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial
4
Bringing the Voice of Clinical Practice and Patients into Drug Development
5